En español

Misuse of Prescription Drugs


  1. Substance Abuse Center for Behavioral Health Statistics and Quality. Results from the 2016 National Survey on Drug Use and Health: Detailed Tables. SAMHSA. https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2016/NSDUH-DetTabs-2016.htm. Published September 7, 2017. Accessed March 7, 2018.
  2. Blanco C, Alderson D, Ogburn E, et al. Changes in the prevalence of non-medical prescription drug use and drug use disorders in the United States: 1991–1992 and 2001–2002. Drug Alcohol Depend. 2007;90(2-3):252-260. doi:10.1016/j.drugalcdep.2007.04.005.
  3. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Treatment Episode Data Set (TEDS): 2003-2013. National Admissions to Substance Abuse Treatment Services. 2015. http://www.samhsa.gov/data/sites/default/files/2013_Treatment_Episode_Data_Set_National/2013_Treatment_Episode_Data_Set_National.pdf.
  4. Center for Behavioral Health Statistics and Quality (CBHSQ). Drug Abuse Warning Network: 2011: Selected Tables of National Estimates of Drug-Related Emergency Department Visits. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2013.
  5. Jones CM, McAninch JK. Emergency Department Visits and Overdose Deaths From Combined Use of Opioids and Benzodiazepines. Am J Prev Med. 2015;49(4):493-501. doi:10.1016/j.amepre.2015.03.040.
  6. Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in Drug and Opioid Overdose Deaths - United States, 2000-2014. MMWR Morb Mortal Wkly Rep. 2016;64(50-51):1378-1382. doi:10.15585/mmwr.mm6450a3.
  7. CDC. CDC Wonder Multiple Cause of Death. http://wonder.cdc.gov/wonder/help/mcd.html.
  8. Centers for Disease Control and Prevention (CDC). Vital signs: overdoses of prescription opioid pain relievers–United States, 1999-2008. MMWR Morb Mortal Wkly Rep. 2011;60(43):1487-1492.
  9. Manchikanti L, Fellows B, Ailinani H, Pampati V. Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective. Pain Physician. 2010;13(5):401-435.
  10. Daniulaityte R, Falck R, Carlson RG. “I’m not afraid of those ones just ‘cause they’ve been prescribed”: Perceptions of risk among illicit users of pharmaceutical opioids. Int J Drug Policy. 2012;23(5):374-384. doi:10.1016/j.drugpo.2012.01.012.
  11. Webster PC. Oxycodone class action lawsuit filed. Can Med Assoc J. 2012;184(7):E345-E346. doi:10.1503/cmaj.109-4158.
  12. Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of Prescription and Over-the-counter Medications and Dietary Supplements Among Older Adults in the United States. JAMA. 2008;300(24):2867. doi:10.1001/jama.2008.892.
  13. Centers for Disease Control and Prevention (CDC). Vital signs: overdoses of prescription opioid pain relievers and other drugs among women--United States, 1999-2010. MMWR Morb Mortal Wkly Rep. 2013;62(26):537-542.
  14. Miech R, Johnston L, O’Malley PM, Keyes KM, Heard K. Prescription Opioids in Adolescence and Future Opioid Misuse. Pediatrics. 2015;136(5):e1169-e1177. doi:10.1542/peds.2015-1364.
  15. Johnston, L.D.; Meich, R.A., O’Malley, P.M.; Bachman, J.G.; Schulenberg, J.E.; and Patrick, M.E. Monitoring the Future National Results on Adolescent Drug Use: 1975-2017. Overview, Key Findings on Adolescent Drug Use. Ann Arbor: Institute for Social Research, The University of Michigan. Available at: www.monitoringthefuture.org
  16. McCabe SE, Teter CJ, Boyd CJ. Illicit use of prescription pain medication among college students. Drug Alcohol Depend. 2005;77(1):37-47. doi:10.1016/j.drugalcdep.2004.07.005.
  17. Boyd CJ, Esteban McCabe S, Teter CJ. Medical and nonmedical use of prescription pain medication by youth in a Detroit-area public school district. Drug Alcohol Depend. 2006;81(1):37-45. doi:10.1016/j.drugalcdep.2005.05.017.
  18. McCabe SE. Medical and Nonmedical Use of Prescription Opioids Among High School Seniors in the United States. Arch Pediatr Adolesc Med. 2012;166(9):797. doi:10.1001/archpediatrics.2012.85.
  19. Young AM, Glover N, Havens JR. Nonmedical Use of Prescription Medications Among Adolescents in the United States: A Systematic Review. J Adolesc Health. 2012;51(1):6-17. doi:10.1016/j.jadohealth.2012.01.011.
  20. Wang R, Chen L, Fan L, et al. Incidence and Effects of Polypharmacy on Clinical Outcome among Patients Aged 80+: A Five-Year Follow-Up Study. PloS One. 2015;10(11):e0142123. doi:10.1371/journal.pone.0142123.
  21. Cotto JH, Davis E, Dowling GJ, Elcano JC, Staton AB, Weiss SRB. Gender effects on drug use, abuse, and dependence: a special analysis of results from the National Survey on Drug Use and Health. Gend Med. 2010;7(5):402-413. doi:10.1016/j.genm.2010.09.004.
  22. Centers for Disease Control and Prevention. CDC Vital Signs Prescription Painkiller Overdoses: A Growing Epidemic, Especially Among Women. July 2013. http://www.cdc.gov/vitalsigns/PrescriptionPainkillerOverdoses/index.html.
  23. Ronan MV, Herzig SJ. Hospitalizations Related To Opioid Abuse/Dependence And Associated Serious Infections Increased Sharply, 2002-12. Health Aff (Millwood). 2016;35(5):832-837. doi:10.1377/hlthaff.2015.1424.
  24. Jones CM, Paulozzi LJ, Mack KA, Centers for Disease Control and Prevention (CDC). Alcohol involvement in opioid pain reliever and benzodiazepine drug abuse-related emergency department visits and drug-related deaths - United States, 2010. MMWR Morb Mortal Wkly Rep. 2014;63(40):881-885.
  25. Pentel P. Toxicity of Over-the-Counter Stimulants. JAMA J Am Med Assoc. 1984;252(14):1898. doi:10.1001/jama.1984.03350140044023.
  26. Gutstein H, Akil H. Opioid Analgesics. In: Goodman & Gilman’s the Pharmacological Basis of Therapeutics. 11th ed. McGraw-Hill; 2006:547-590.
  27. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. MMWR Recomm Rep Morb Mortal Wkly Rep Recomm Rep Cent Dis Control. 2016;65(1):1-49. doi:10.15585/mmwr.rr6501e1.
  28. Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L. A comprehensive review of opioid-induced hyperalgesia. Pain Physician. 2011;14(2):145-161.
  29. Hart CL, Ksir C. Drugs, Society & Human Behavior. 15th ed. New York, NY: McGraw-Hill; 2013.
  30. Jones CM, Lurie PG, Throckmorton DC. Effect of US Drug Enforcement Administration’s Rescheduling of Hydrocodone Combination Analgesic Products on Opioid Analgesic Prescribing. JAMA Intern Med. January 2016. doi:10.1001/jamainternmed.2015.7799.
  31. Medline Plus. Oxycodone. March 2016. https://www.nlm.nih.gov/medlineplus/druginfo/meds/a682132.html.
  32. Medline Plus. Oxymorphone. March 2016. https://www.nlm.nih.gov/medlineplus/druginfo/meds/a610022.html#why.
  33. Cicero TJ, Ellis MS. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin. JAMA Psychiatry. 2015;72(5):424-430. doi:10.1001/jamapsychiatry.2014.3043.
  34. O’Brien CP, Dackis C. Principles of the Pharmacotherapy of Addictive Disorders. In: Neurobiology of Mental Illness. Third. Oxford University Press; 2009:867-880.
  35. O’Brien CP. Drug Addiction and Drug Abuse. In: Goodman & Gilman’s the Pharmacological Basis of Therapeutics. 11th ed. McGraw-Hill; 2006:607-627.
  36. Institute of Medicine (U.S.), ed. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington, D.C: National Academies Press; 2011.
  37. Chou R, Turner JA, Devine EB, et al. The Effectiveness and Risks of Long-Term Opioid Therapy for Chronic Pain: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med. 2015;162(4):276. doi:10.7326/M14-2559.
  38. Hypnotics and Sedatives. In: Goodman & Gilman’s the Pharmacological Basis of Therapeutics. 11th ed. McGraw-Hill; 2006:401-427.
  39. Gunja N. The Clinical and Forensic Toxicology of Z-drugs. J Med Toxicol. 2013;9(2):155-162. doi:10.1007/s13181-013-0292-0.
  40. Sellers EM. Alcohol, barbiturate and benzodiazepine withdrawal syndromes: clinical management. CMAJ Can Med Assoc J. 1988;139(2):113-120.
  41. Ciccarone D. Stimulant Abuse: Pharmacology, Cocaine, Methamphetamine, Treatment, Attempts at Pharmacotherapy. Prim Care Clin Off Pract. 2011;38(1):41-58. doi:10.1016/j.pop.2010.11.004.
  42. Campion EW, Scammell TE. Narcolepsy. N Engl J Med. 2015;373(27):2654-2662. doi:10.1056/NEJMra1500587.
  43. Santosh PJ, Sattar S, Canagaratnam M. Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults. CNS Drugs. 2011;25(9):737-763. doi:10.2165/11593070-000000000-00000.
  44. Corp SA, Gitlin MJ, Altshuler LL. A review of the use of stimulants and stimulant alternatives in treating bipolar depression and major depressive disorder. J Clin Psychiatry. 2014;75(9):1010-1018. doi:10.4088/JCP.13r08851.
  45. Westfall TC, Westfall DP. Adrenergic Agonists and Antagonists. In: Goodman & Gilman’s the Pharmacological Basis of Therapeutics. 11th ed. McGraw-Hill; 2006:237-295.
  46. McCabe SE, West BT. Medical and Nonmedical Use of Prescription Stimulants: Results From a National Multicohort Study. J Am Acad Child Adolesc Psychiatry. 2013;52(12):1272-1280. doi:10.1016/j.jaac.2013.09.005.
  47. Schelle KJ, Faulmüller N, Caviola L, Hewstone M. Attitudes toward pharmacological cognitive enhancement–a review. Front Syst Neurosci. 2014;8. doi:10.3389/fnsys.2014.00053.
  48. Caldwell JA, Caldwell JL. Fatigue in military aviation: an overview of US military-approved pharmacological countermeasures. Aviat Space Environ Med. 2005;76(7 Suppl):C39-C51.
  49. Hyman SE. Cognitive Enhancement: Promises and Perils. Neuron. 2011;69(4):595-598. doi:10.1016/j.neuron.2011.02.012.
  50. Tolia VN, Patrick SW, Bennett MM, et al. Increasing Incidence of the Neonatal Abstinence Syndrome in U.S. Neonatal ICUs. N Engl J Med. April 2015:150426153016002. doi:10.1056/NEJMsa1500439.
  51. Patrick SW, Davis MM, Lehmann CU, Cooper WO. Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012. J Perinatol Off J Calif Perinat Assoc. 2015;35(8):650-655. doi:10.1038/jp.2015.36.
  52. National Center for Health Statistics, CDC. Ambulatory Care Use and Physician office visits. 2014. http://www.cdc.gov/nchs/fastats/physician-visits.htm.
  53. Rasubala L, Pernapati L, Velasquez X, Burk J, Ren Y-F. Impact of a Mandatory Prescription Drug Monitoring Program on Prescription of Opioid Analgesics by Dentists. Narendran R, ed. PLOS ONE. 2015;10(8):e0135957. doi:10.1371/journal.pone.0135957.
  54. Johnson H, Paulozzi L, Porucznik C, Mack K, Herter B, Hal Johnson Consulting and Division of Disease Control and Health Promotion, Florida Department of Health. Decline in drug overdose deaths after state policy changes - Florida, 2010-2012. MMWR Morb Mortal Wkly Rep. 2014;63(26):569-574.
  55. Rutkow L, Chang H-Y, Daubresse M, Webster DW, Stuart EA, Alexander GC. Effect of Florida’s Prescription Drug Monitoring Program and Pill Mill Laws on Opioid Prescribing and Use. JAMA Intern Med. 2015;175(10):1642-1649. doi:10.1001/jamainternmed.2015.3931.
  56. Franklin G, Sabel J, Jones CM, et al. A Comprehensive Approach to Address the Prescription Opioid Epidemic in Washington State: Milestones and Lessons Learned. Am J Public Health. 2015;105(3):463-469. doi:10.2105/AJPH.2014.302367.
  57. FDA. Disposal of Unused Medicines: What You Should Know. October 2015. http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/EnsuringSafeUseofMedicine/SafeDisposalofMedicines/ucm186187.htm.
  58. Simon K, Worthy SL, Barnes MC, Tarbell B. Abuse-deterrent formulations: transitioning the pharmaceutical market to improve public health and safety. Ther Adv Drug Saf. 2015;6(2):67-79. doi:10.1177/2042098615569726.
  59. Maldonado R, Baños JE, Cabañero D. The endocannabinoid system and neuropathic pain. Pain. 2016;157 Suppl 1:S23-S32. doi:10.1097/j.pain.0000000000000428.
  60. NIDA. Principles of Drug Addiction Treatment: A Research-Based Guide (Third Edition). December 2012. https://d14rmgtrwzf5a.cloudfront.net/sites/default/files/podat_1.pdf.
  61. Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-Assisted Therapies—Tackling the Opioid-Overdose Epidemic. N Engl J Med. 2014;370(22):2063-2066. doi:10.1056/NEJMp1402780.
  62. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics, and Quality. Treatment Episode Data Set (TEDS) 2002 - 2012: National Admissions to Substance Abuse Treatment Services. 2014. http://www.samhsa.gov/data/sites/default/files/TEDS2012N_Web.pdf.
  63. Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment. Am J Public Health. 2015;105(8):e55-e63. doi:10.2105/AJPH.2015.302664.
  64. Obama Administration Takes More Actions to Address the Prescription Opioid and Heroin Epidemic. July 2016. https://www.whitehouse.gov/the-press-office/2016/07/05/obama-administration-takes-more-actions-address-prescription-opioid-and.
  65. Fiellin DA, Schottenfeld RS, Cutter CJ, Moore BA, Barry DT, O’Connor PG. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial. JAMA Intern Med. 2014;174(12):1947-1954. doi:10.1001/jamainternmed.2014.5302.
  66. D’Onofrio G, O’Connor PG, Pantalon MV, et al. Emergency Department–Initiated Buprenorphine/Naloxone Treatment for Opioid Dependence: A Randomized Clinical Trial. JAMA. 2015;313(16):1636. doi:10.1001/jama.2015.3474.
  67. Gordon MS, Kinlock TW, Schwartz RP, Fitzgerald TT, O’Grady KE, Vocci FJ. A randomized controlled trial of prison-initiated buprenorphine: prison outcomes and community treatment entry. Drug Alcohol Depend. 2014;142:33-40. doi:10.1016/j.drugalcdep.2014.05.011.
  68. Kinlock TW, Gordon MS, Schwartz RP, O’Grady K, Fitzgerald TT, Wilson M. A randomized clinical trial of methadone maintenance for prisoners: results at 1-month post-release. Drug Alcohol Depend. 2007;91(2-3):220-227. doi:10.1016/j.drugalcdep.2007.05.022.
  69. Lee JD, Friedmann PD, Kinlock TW, et al. Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders. N Engl J Med. 2016;374(13):1232-1242. doi:10.1056/NEJMoa1505409.
  70. Darker CD, Sweeney BP, Barry JM, Farrell MF, Donnelly-Swift E. Psychosocial interventions for benzodiazepine harmful use, abuse or dependence. Cochrane Database Syst Rev. 2015;5:CD009652. doi:10.1002/14651858.CD009652.pub2.
  71. Jones JD, Mogali S, Comer SD. Polydrug abuse: A review of opioid and benzodiazepine combination use. Drug Alcohol Depend. 2012;125(1-2):8-18. doi:10.1016/j.drugalcdep.2012.07.004.

This page was last updated January 2018

Get this Publication

Ordering Publications

Call 1-877-643-2644 or:
NIDA Drug Pubs
Cite this article

NIDA. (2018, January 17). Misuse of Prescription Drugs. Retrieved from https://www.drugabuse.gov/publications/research-reports/misuse-prescription-drugs

press ctrl+c to copy
NIDA Notes: The Latest in Drug Abuse Research

​Research Reports

This series of reports simplifies the science of research findings for the educated lay public, legislators, educational groups, and practitioners. The series reports on research findings of national interest.

Lesson Plan and Activity Finder